Simply Wall St.1d agoneutral
Iovance Biotherapeutics (IOVA) Q3 Earnings Sharpen Focus On Margin RecoveryNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
107last 24h
3125last 7d
511● bullish (7d)
311● bearish (7d)
227publishers
GuruFocus.com2d agoneutral
Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122 Million ...MT Newswires5d agoneutral
UBS Adjusts Price Target on Iovance Biotherapeutics to $8 From $7, Maintains Neutral RatingInvestor's Business Daily9d agobearish
Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer TwistStocktwits40d agoneutral
IOVA Stock Hits Over 2-Year Highs - Why Iovance Raised Its FY2026 Revenue OutlookInvesting.com40d agobullish
Iovance shares jump in premarket as raised outlook clears consensus viewsSimply Wall St.85d agoneutral
Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance?